MorphoSys AG (MPSYF)
- Previous Close
71.38 - Open
71.38 - Bid --
- Ask --
- Day's Range
71.38 - 71.38 - 52 Week Range
19.66 - 72.71 - Volume
79 - Avg. Volume
12,895 - Market Cap (intraday)
2.745B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-5.93 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.
www.morphosys.comRecent News: MPSYF
Performance Overview: MPSYF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MPSYF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MPSYF
Valuation Measures
Market Cap
2.75B
Enterprise Value
2.70B
Trailing P/E
24.24
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.61
Price/Book (mrq)
51.30
Enterprise Value/Revenue
11.31
Enterprise Value/EBITDA
-38.21
Financial Highlights
Profitability and Income Statement
Profit Margin
-79.63%
Return on Assets (ttm)
-6.82%
Return on Equity (ttm)
-183.80%
Revenue (ttm)
238.28M
Net Income Avi to Common (ttm)
-189.73M
Diluted EPS (ttm)
-5.93
Balance Sheet and Cash Flow
Total Cash (mrq)
678.58M
Total Debt/Equity (mrq)
3,454.18%
Levered Free Cash Flow (ttm)
-165.35M
Company Insights: MPSYF
MPSYF does not have Company Insights